Skip to content
ASCO 2012 logo

ASCO 2012

4 interviews

American Society of Clinical Oncology Annual Meeting

Interviews and expert commentary from ASCO 2012 — study authors and key opinion leaders discuss the findings and their clinical implications.

Official website ↗
ASCO 2012 ANNUAL MEETING: Outgoing ASCO President Michael Link Comments On Key New Clinical Research Findings

ASCO 2012 ANNUAL MEETING: Outgoing ASCO President Michael Link Comments On Key New Clinical Research Findings

CHICAGO—The outgoing president of ASCO, Dr Michael Link from Stanford University School of Medicine in California, answers questions from Peter Goodwin about the progress achieved in cancer clinical s

11 June 2012
ASCO 2012 ANNUAL MEETING: Targeted Drug Afatinib Delays Progression of Advanced Lung Cancers, Particularly Those With Specific Genetic Mutations

ASCO 2012 ANNUAL MEETING: Targeted Drug Afatinib Delays Progression of Advanced Lung Cancers, Particularly Those With Specific Genetic Mutations

CHICAGO—Findings from a Phase III trial show that initial single-agent therapy with a new oral drug called afatinib prolongs progression- free survival in patients with advanced lung adenocarcinomas t

11 June 2012
Childhood Cancer Treatment: Model For Adult Therapy — ASCO President

Childhood Cancer Treatment: Model For Adult Therapy — ASCO President

STOCKHOLM—The first specialist in pediatric oncology ever to hold office as President of the American Society of Clinical Oncology, Dr Michael Link — Professor of Pediatrics at Stanford University Sch

10 June 2012